Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:NUVL NASDAQ:TGTX NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$71.52-2.8%$79.04$69.12▼$122.83$4.95B0.12979,188 shs286,695 shsNUVLNuvalent$83.73-2.3%$76.94$55.54▼$113.51$6.03B1.31504,610 shs98,113 shsTGTXTG Therapeutics$38.47-1.8%$36.33$16.65▼$46.48$6.11B1.912.46 million shs670,776 shsVERAVera Therapeutics$23.33-1.8%$22.75$18.53▼$51.61$1.49B1.19994,901 shs191,755 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus-1.09%-12.20%-5.54%-27.36%-39.48%NUVLNuvalent+0.28%+4.41%+12.66%+19.61%+6.45%TGTXTG Therapeutics+0.90%+4.04%+11.97%+2.27%+77.49%VERAVera Therapeutics+0.85%-2.42%+12.34%+11.60%-32.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNTHLantheus4.5785 of 5 stars3.42.00.04.22.92.51.9NUVLNuvalent3.3229 of 5 stars4.61.00.00.02.93.30.0TGTXTG Therapeutics3.4082 of 5 stars2.40.00.03.51.62.51.9VERAVera Therapeutics4.1186 of 5 stars4.65.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.83Moderate Buy$131.2079.51% UpsideNUVLNuvalent 3.17Buy$119.6039.18% UpsideTGTXTG Therapeutics 2.80Moderate Buy$43.8012.56% UpsideVERAVera Therapeutics 3.10Buy$65.00175.31% UpsideCurrent Analyst Ratings BreakdownLatest VERA, TGTX, NUVL, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform7/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.006/30/2025NUVLNuvalentThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/25/2025NUVLNuvalentRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$105.00 ➝ $112.006/24/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$115.006/24/2025NUVLNuvalentLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $140.006/24/2025NUVLNuvalentHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $130.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.53B3.30$6.97 per share10.49$15.65 per share4.67NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ATGTXTG Therapeutics$329M18.78$0.12 per share323.77$1.43 per share27.21VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$312.44M$3.5220.8411.58N/A16.55%36.99%20.55%7/30/2025 (Estimated)NUVLNuvalent-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24163.0638.91N/A10.13%18.88%7.05%8/5/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest VERA, TGTX, NUVL, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NUVLNuvalent-$1.27N/AN/AN/AN/AN/A8/14/2025Q2 2025VERAVera Therapeutics-$0.82N/AN/AN/AN/AN/A8/5/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.495.745.46NUVLNuvalentN/A14.4814.48TGTXTG Therapeutics1.034.023.04VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%NUVLNuvalent97.26%TGTXTG Therapeutics58.58%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipLNTHLantheus1.50%NUVLNuvalent10.20%TGTXTG Therapeutics10.64%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus70069.19 million68.15 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableVERAVera Therapeutics4063.77 million53.38 millionOptionableVERA, TGTX, NUVL, and LNTH HeadlinesRecent News About These CompaniesVera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Consensus PT from AnalystsJuly 18 at 2:37 AM | americanbankingnews.comStartup targets orphan kidney disease with former Merck drugJuly 17 at 2:38 PM | medcitynews.comMReviewing Celcuity (NASDAQ:CELC) and Vera Therapeutics (NASDAQ:VERA)July 16 at 2:21 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 15 at 2:29 AM | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2025 | globenewswire.comVera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA NephropathyJuly 6, 2025 | msn.comVera Therapeutics Inc Class A Sustainability - MorningstarJuly 5, 2025 | morningstar.comMVera Therapeutics director Enright buys shares worth $5.2mJune 27, 2025 | investing.comVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingJune 27, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying ActivityJune 26, 2025 | marketbeat.comInsider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of StockJune 26, 2025 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 SharesJune 25, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 SharesJune 25, 2025 | marketbeat.comPolycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsightJune 24, 2025 | theglobeandmail.comBAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsightJune 24, 2025 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateJune 18, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)...June 12, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomBuffett's $2B+ Bet With Big Long-Term Potential Just Got UpgradedBy Leo Miller | July 10, 2025View Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded5 Small Cap Stocks With Explosive Upside PotentialBy Ryan Hasson | June 23, 2025View 5 Small Cap Stocks With Explosive Upside Potential3 Retail Stocks to Watch as Back-to-School Spending Ramps UpBy Chris Markoch | July 14, 2025View 3 Retail Stocks to Watch as Back-to-School Spending Ramps UpVERA, TGTX, NUVL, and LNTH Company DescriptionsLantheus NASDAQ:LNTH$71.52 -2.08 (-2.83%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Nuvalent NASDAQ:NUVL$83.72 -1.97 (-2.29%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$38.47 -0.73 (-1.85%) As of 12:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Vera Therapeutics NASDAQ:VERA$23.33 -0.43 (-1.81%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Full Steam Ahead: The Bullish Case for Carnival Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
